When it comes to submitting plans for a drug marketing authorization application (MAA) for evaluation via the EU’s centralized procedure, the European Medicines Agency says there are clear examples of “good and bad behavior” from companies that can affect the efficiency of its processes.
The EMA requires companies to notify their intent to submit an initial MAA around seven months prior to the intended...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?